Payment overview · 2025
General Payments
$114.46
5 reported records · 5 companies
Healthcare provider profile · identity verified
Audrey Liu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DELRAY BEACH, FL · NPI 1568404663
Verified facts
What the public records show
CMS Open Payments records show Audrey Liu, M.D. received $114.46 in general payments during 2025 across 5 reported records.
Philips North America LLC accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.67 | 28.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.78 | 20.8% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.43 | 20.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.08 | 16.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.50 | 13.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $114.46 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 833 | 241 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 797 | 241 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 147 |
| Alprazolam | Alprazolam | 390 | 86 |
| Losartan Potassium | Losartan Potassium | 345 | 104 |
| Omeprazole | Omeprazole | 262 | 76 |
| Trazodone Hcl | Trazodone Hcl | 257 | 85 |
| Lisinopril | Lisinopril | 245 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 64 |
| Ezetimibe | Ezetimibe | 220 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 41 |
| Metformin Hcl | Metformin Hcl | 173 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 49 |
| Montelukast Sodium | Montelukast Sodium | 159 | 49 |
| Simvastatin | Simvastatin | 156 | 45 |
| Ozempic | Semaglutide | 149 | 25 |
| Metformin Hcl Er | Metformin Hcl | 146 | 46 |
| Lorazepam | Lorazepam | 143 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 41 |
| Gabapentin | Gabapentin | 136 | 57 |
| Sertraline Hcl | Sertraline Hcl | 131 | 41 |
| Clonazepam | Clonazepam | 125 | 26 |
| Atenolol | Atenolol | 123 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 34 |
| Potassium Chloride | Potassium Chloride | 108 | 26 |
| Famotidine | Famotidine | 101 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 44 |
| Furosemide | Furosemide | 96 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 27 |
| Jardiance | Empagliflozin | 93 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 23 |
| Valsartan | Valsartan | 85 | 26 |
| Bupropion Xl | Bupropion Hcl | 82 | 26 |
| Eliquis | Apixaban | 80 | 26 |
| Temazepam | Temazepam | 69 | 13 |
| Finasteride | Finasteride | 68 | 21 |
| Synthroid | Levothyroxine Sodium | 68 | 24 |
| Diazepam | Diazepam | 59 | 14 |
| Alendronate Sodium | Alendronate Sodium | 58 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 19 |
| Mirtazapine | Mirtazapine | 54 | 17 |
| Glimepiride | Glimepiride | 52 | 17 |
| Tramadol Hcl | Tramadol Hcl | 51 | 12 |
| Valacyclovir | Valacyclovir Hcl | 51 | 26 |
| Methylprednisolone | Methylprednisolone | 50 | 44 |
| Myrbetriq | Mirabegron | 49 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 17 |
| Allopurinol | Allopurinol | 48 | 16 |
| Azithromycin | Azithromycin | 48 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Irbesartan | Irbesartan | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Prolia | Denosumab | 42 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 34 |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Meloxicam | Meloxicam | 40 | 14 |
| Carvedilol | Carvedilol | 39 | 12 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 12 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 11 |
| Amoxicillin | Amoxicillin | 33 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Propranolol Hcl | Propranolol Hcl | 33 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 11 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 21 |
| Risedronate Sodium | Risedronate Sodium | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $114.46 · 5 records | Philips North America LLC | Ambulatory Monitoring & Diagnostics Undivided, CAPVAXIVE, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, REZDIFFRA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error